GW & Wade’s Arcutis Biotherapeutics ARQT Stock Holding History

GW & Wade’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$172K	Buy	53,100 +13,700	+35%	+$37.2K	0.01%	396
2023 Q3	$209K	Buy	39,400 +24,700	+168%	+$210K	0.01%	379
2023 Q2	$140K	Hold	14,700	–	–	0.01%	376
2023 Q1	$162K	Buy	14,700 +1,600	+12%	+$23.1K	0.01%	362
2022 Q4	$194K	Hold	13,100	–	–	0.01%	368
2022 Q3	$250K	Hold	13,100	–	–	0.01%	326
2022 Q2	$279K	Hold	13,100	–	–	0.01%	317
2022 Q1	$252K	Hold	13,100	–	–	0.01%	341
2021 Q4	$272K	Buy	+13,100	New	+$261K	0.01%	335

Other funds holding ARQT

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

GW & Wade's ARQT Position: Q4 2023 in Review

GW & Wade increased its Arcutis Biotherapeutics (ARQT) stake by 35% in Q4 2023, buying an estimated $37.2K and bringing the position to 53,100 shares worth $172K. The position accounts for 0.01% of the portfolio, ranked #396.

GW & Wade first reported a position in ARQT in Q4 2021 and has held it in 9 quarters since. The position peaked at $279K in Q2 2022. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

GW & Wade held 53,100 shares of Arcutis Biotherapeutics worth $172K as of Q4 2023.
GW & Wade bought 13,700 Arcutis Biotherapeutics shares in Q4 2023, an estimated $37.2K.
Arcutis Biotherapeutics made up 0.01% of GW & Wade's portfolio in Q4 2023, its #396 holding.
GW & Wade first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
GW & Wade's Arcutis Biotherapeutics position peaked at $279K in Q2 2022.
133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.